自身免疫性肝病基础和临床研究进展

张玲娟; 古春昱; 胥佳; 马静婷; 李东复

doi:10.3969/j.issn.1001-5256.2014.05.021

自身免疫性肝病基础和临床研究进展

DOI: 10.3969/j.issn.1001-5256.2014.05.021

吉林大学第二医院消化内科

详细信息

中图分类号: R575
计量
- 文章访问数: 230
- HTML全文浏览量: 14
- PDF下载量: 440
- 被引次数: 0
出版历程
- 出版日期: 2014-05-20

Basic and clinical progress in autoimmune liver disease

摘要

摘要:
自身免疫性肝病与常见肝病的差异性较大,提高其认知度和诊断水平尤为重要。回顾了有关自身免疫性肝病最近几年的文献资料,总结了自身免疫性肝病的发病机制、自身抗体、诊断及治疗方面取得的进展,指出还须进一步的临床研究及实践加以证实和完善。
- 自身免疫性疾病 /
- 肝疾病 /
- 自身抗体 /
- 综述
Abstract:
Autoimmune liver disease ( AILD) is substantially different from common liver diseases, and it is very important to improve its recognition and diagnostic level. The literature on AILD published in recent years is reviewed, and the advances in pathogenesis, autoantibodies, diagnosis, and treatment of AILD are summarized. However, it is pointed out that further clinical research and practice are needed for better diagnosis and treatment of AILD.
- hepatitis, autoimmune /
- liver diseases /
- autoantibodies /
- review

HTML全文

参考文献(32)

[1]JIANG H, CHESS L.Regulation of immune responses by T cells[J].N Engl J Med, 2006, 354 (11) :1166-1176.

[2]OKUMURA A, ISHIKAWA, SATO S, et al.Deficieccy of forkhead box P3 and cytotoxic T-lymphocyte-associated antigen-4 gene expressions and impaired suppressor function of CD4 (+) CD25 (+) T cells in patients with autoimmune hepatitis[J].Hepatol Res, 2008, 38 (9) :896-903.

[3]PEISELER M, SEBODE M, FRANKE B, et al.FOXP3+regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency[J].J Hepatol, 2012, 57 (1) :125-132.

[4]LONGHI MS, MA Y, MIELI-VERGANI G, et al.Regulatory T cells in autoimmune hepatitis[J].J Hepatol, 2012, 57 (4) :932-933.

[5]ZHAO L, TANG Y, YOU Z, et al.Interleukin-17 contributes to the pathogenesis of autoimune hepatitis through inducing hepatic in Interleukin-6 expression[J].PLoS One, 2011, 6 (4) :e18909.

[6]WEI LL, ZHOU L, SHI HB, et al.Role of Th17 cells in common liver disease[J].J Clin Hepatol, 2013, 29 (6) :477-480. (in Chinese) 魏琳琳, 周莉, 时红波, 等.Th17在常见肝脏疾病中的作用[J].临床肝胆病杂志, 2013, 29 (6) :477-480.

[7]LIU JT.Clinical application and diagnostic significance of autoantibody detection in autoimmune liver diseases[J].Immunol J, 2013, 29 (3) :267-269. (in Chinese) 刘金涛.自身抗体测定在临床自身免疫性肝病中的作用和诊断意义[J].免疫学杂志, 2013, 29 (3) :267-269.

[8]WANG QX, JIANG WJ, MIAO Q, et al.Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients:a single center experience[J].J Dig Dis, 2013, 14 (4) :175-180.

[9]CZAJA AJ.Drug choices in autoimmune hepatitis:part A-Steroids[J].Expert Rev Gastroenterol Hepatol, 2012, 6 (5) :603-615.

[10]CZAJA AJ.Nonstandard drugs and feasible new interventions for autoimmune hepatitis:partⅡ[J].Inflamm Allergy Drug Targets, 2012, 11 (5) :351-363.

[11]LIU JZ, ALMARRI MA, GAFFNEY DJ, et al.Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis[J].Nat Genet, 2012, 44 (10) :1137-1141.

[12]LLEO A, LIAO J, INVERNIZZI P, et al.Immunoglobulin M levels inversely correlate with CD40 ligand promoter methylation in patients with primary biliary cirrhosis[J].Hepatology, 2012, 55 (1) :153-160.

[13]HIRSCHFILED GM, INVERNIZZI P.Progress in the genetics of primary biliary cirrh-osis[J].Semin Liver Dis, 2011, 31 (2) :147-156.

[14]ZHANG Y, CHEN WZ, WANG WM, et al.Effect of estrogen receptorαgene polymorp-hism on the variations of T lymphocyte subsets and its related cell factors within female primary cholestasis cirrhosis patient[J].Chin J Clinicians:Electronic Edition, 2010, 4 (7) :954-961. (in Chinese) 张嫣, 陈伟忠, 王伟民, 等.雌激素受体α基因多态性对女性原发性胆汁淤积性肝硬化患者T细胞亚群及其相关细胞因子变化影响的研究[J].中华临床医师杂志:电子版, 2010, 4 (7) :954-961.

[15]LIANG Y, YANG Z, ZHONG R.Smoking, family history and urinary tract infection are associated with primary biliary cirrhosis:a meta-analysis[J].Hepatol Res, 2011, 41 (6) :572-578.

[16]NINOMIVA M, UENO Y, SHIMOSEGAWA T.PBC:Animal models of cholangiopathies and possible endogenous viral infections[J].Int J Hepatol, 2012, 2012:649290.

[17]SELMI C, BOWLUS C, GERSHWIN ME, et al.Primary biliary cirrhosis[J].Lancet, 2011, 377 (9777) :1600-1609.

[18]SHI J, YUAN SM, LI P, et al.Level and significance of detection of primary biliary cir-rhosis patients with serum MIP-3αand IL-17A[J].Chin J Clin Lab Sci, 2013, 31 (2) :96-98. (in Chinese) 史静, 袁世梅, 李朴, 等.检测原发性胆汁性肝硬化患者血清MIP-3α与IL-17A的水平及意义[J].临床检验杂志, 2013, 31 (2) :96-98.

[19]KHAN F, KOMARLA AR, MENDOZA PG, et al.Keratin 19 demonstration of canal of Hering loss in primary biliary cirrhosis:”minimal change PBC”?[J].Hepatology, 2013, 57 (2) :700-707.

[20]ANGULO P, JORGENSEN RA, KEACH JC, et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid[J].Hepatology, 2000, 31 (2) :318-323.

[21]RITZEL U, LEONHARDT U, NATHER M, et al.Simvastatin in primary biliary cirrhosis:effects on serum lipids and distinct disease markets[J].J Hepatol, 2002, 36 (6) :454-458.

[22] TSUDA M, MORITOKI Y, LIAN ZX, et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology, 2012, 55 (2) :512-521.

[23]HOU XM, JIN EH, ZHANG J, et al.Magnetic resonance cholangiopancreatographic features of primary sclerosing cholangitis[J].Chin J Med Imaging Technol, 2013, 29 (10) :1670-1673. (in Chinese) 侯新萌, 靳二虎, 张洁, 等.原发性硬化性胆管炎的磁共振胰胆管成像表现[J].中国医学影像技术, 2013, 29 (10) :1670-1673.

[24]WANG QY, LIU WQ.One case report of Traditional Chinese Medicine treatment of primary sclerosing cholangitis[J].J Changchun Univ Tradit Chin Med, 2012, 28 (1) :89-90. (in Chinese) 王庆艳, 刘文全.中医药治疗原发性硬化性胆管炎1例[J].长春中医药大学学报, 2012, 28 (1) :89-90.

[25]BERGQUIST A, MONTGOMERY SM, BAHMANYAR S, et al.Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis[J].Clin Gastroenterol Hepatol, 2008, 6 (8) :939-943.

[26]POLLHEIMER MJ, HALILBASIC E, FICKERT P, et al.Pathogenesis of primary scl-erosing cholangitis[J].Best Pract Res Clin Gastroenterol, 2011, 25 (6) :727-739.

[27]RIGOPOULOU EI, SMYK DS, MATTHEWS CE, et al.Epsteinbarr virus as a trigger of autoimmune liver diseases[J].Adv Virol, 2012, 2012:987471.

[28]NAVANEETHAN U, VENKATESH PG, CHOUDHARY M, et al.Elevated immunoglobulin G4 level is associated with reduced colectomy-free survival in patients with primary sclerosing cholangitis and ulcerative colitis[J].J Crohns Colitis, 2013, 7 (2) :e35-e41.

[29]KATO T, KOMORI A, BAE SK, et al.Concurrent systemic AA amyloidosis can discriminate primary sclerosing cholangitis from IgG4-associated cholangitis[J].World J Gastroenterol, 2012, 18 (2) :192-196.

[30]KRONES E, GRAZIADEI I, TRAUNER M, et al.Evolving concepts in primary sclerosing cholangitis[J].Liver Int, 2012, 32 (3) :352-369.

[31]OTHMAN MO, DUNKELBERG J, ROY PK.Urosdeoxycholic acid in primary sclerosing cholangitis:a meta-analysis and systematic review[J].Arab J Gastroenterol, 2012, 13 (3) :103-110.

[32]SINGH S, KHANNA S, PARDI DS, et al.Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatoy bowel disease:a systematic review and meta-analysis[J].Inflamm Bowel Dis, 2013, 19 (8) :1631-1638.

施引文献

资源附件(0)

访问统计